BR0013355A - Tratamento com droga para a sìndrome da perna inquieta - Google Patents

Tratamento com droga para a sìndrome da perna inquieta

Info

Publication number
BR0013355A
BR0013355A BR0013355-8A BR0013355A BR0013355A BR 0013355 A BR0013355 A BR 0013355A BR 0013355 A BR0013355 A BR 0013355A BR 0013355 A BR0013355 A BR 0013355A
Authority
BR
Brazil
Prior art keywords
leg syndrome
drug treatment
restless leg
drug
rls
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BR0013355-8A
Other languages
English (en)
Inventor
Hans-Michael Brecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of BR0013355A publication Critical patent/BR0013355A/pt
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Patente de Invenção: "TRATAMENTO COM DROGA PARA A SìNDROME DA PERNA INQUIETA". A invenção refere-se a uma nova combinação de substâncias ativas para um tratamento mais eficaz da Síndrome da Perna Inquieta (RLS), que consiste em um agonista de <244>-2 e uma outra droga neuropsíquica as quais, quando usadas como uma monoterapia, reduzem os sintomas da RLS.
BR0013355-8A 1999-08-19 2000-08-09 Tratamento com droga para a sìndrome da perna inquieta Pending BR0013355A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19938823A DE19938823A1 (de) 1999-08-19 1999-08-19 Medikamentöse Behandlung des Restless Leg Syndroms
PCT/EP2000/007719 WO2001013903A2 (de) 1999-08-19 2000-08-09 Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid

Publications (1)

Publication Number Publication Date
BR0013355A true BR0013355A (pt) 2002-04-30

Family

ID=7918572

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013355-8A Pending BR0013355A (pt) 1999-08-19 2000-08-09 Tratamento com droga para a sìndrome da perna inquieta

Country Status (21)

Country Link
US (1) US20010053777A1 (pt)
EP (1) EP1210076A2 (pt)
JP (1) JP2003513014A (pt)
KR (1) KR20020020273A (pt)
CN (1) CN1368878A (pt)
AR (1) AR025329A1 (pt)
AU (1) AU6836500A (pt)
BR (1) BR0013355A (pt)
CA (1) CA2382648A1 (pt)
CO (1) CO5190708A1 (pt)
CZ (1) CZ2002516A3 (pt)
DE (1) DE19938823A1 (pt)
IL (1) IL147643A0 (pt)
MX (1) MXPA02001295A (pt)
NO (1) NO20020792L (pt)
PE (1) PE20010738A1 (pt)
PL (1) PL364871A1 (pt)
SK (1) SK2452002A3 (pt)
TR (1) TR200200450T2 (pt)
UY (1) UY26296A1 (pt)
WO (1) WO2001013903A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2314893C (en) 1997-12-22 2005-09-13 Euro-Celtique, S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
NZ522112A (en) * 2000-04-21 2004-10-29 Upjohn Co Substituted phenylazacycloalkane-type compounds for treating fibromyalgia and chronic fatigue syndrome
KR20020089510A (ko) * 2000-04-21 2002-11-29 파마시아 앤드 업존 캄파니 섬유 근육통 증후군 및 만성 피로 증후군의 치료
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
AR031152A1 (es) * 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
PT1380306E (pt) 2001-03-30 2009-05-25 Toray Industries Medicamentos para psiconeurose
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
DE60238756D1 (de) 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
EP1492506B2 (en) * 2002-04-05 2016-06-29 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
PL372695A1 (en) * 2002-06-19 2005-07-25 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DK1426049T3 (da) 2002-12-02 2005-08-22 Sanol Arznei Schwarz Gmbh Iontophoretisk tilförsel af rotigotin til behandling af Parkinsons sygdom
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
AU2006208627B8 (en) * 2005-01-28 2009-08-13 Mundipharma Pty Limited Alcohol resistant dosage forms
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
NZ571591A (en) 2006-04-03 2011-09-30 Teva Pharma Use of rasagiline for the treatment of restless legs syndrome
US20100029618A1 (en) * 2006-12-22 2010-02-04 Gil Daniel W Alpha-2 receptor pan agonist and anticonvulsant compositions for treating chronic pain
WO2009158477A1 (en) * 2008-06-25 2009-12-30 Us Worldmeds Llc Skin patches and sustained-release formulations comprising lofexidine for transdermal and oral delivery
MX347106B (es) 2009-03-10 2017-04-12 Euro-Celtique S A * Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona.
US20180264013A1 (en) * 2010-07-08 2018-09-20 Wellesley Pharmaceuticals, Llc Composition and methods for treating sleep disorders
CA2876203A1 (en) * 2012-06-11 2013-12-19 Psychogenics, Inc. Use of eltoprazine in the treatment of motor and movement disorders associated with the treatment of parkinson's disease
CA2918004C (en) 2013-07-23 2018-11-20 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
ES2847936T3 (es) 2013-10-07 2021-08-04 Teikoku Pharma Usa Inc Métodos y composiciones para el suministro transdérmico de una cantidad no sedante de dexmedetomidina
KR101831290B1 (ko) 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
EP3512600A4 (en) * 2016-09-13 2020-05-27 Mindlab LLC DRUG COMBINATIONS AND TREATMENT OF RESTLESS LEG SYNDROME
LT3906927T (lt) * 2020-05-04 2022-08-10 Bioprojet Pharma Dalinių dopamino d3 agonistų naudojimas centrinės nervų sistemos sutrikimams gydyti
CN115154448B (zh) * 2022-08-04 2024-01-30 谭竞 一种治疗不宁腿综合征的药物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859685A (en) * 1986-08-13 1989-08-22 Boc, Inc. Anesthetic composition and method of using the same
DE19749724A1 (de) * 1997-11-11 1999-06-10 Gruenenthal Gmbh Verwendung einer Kombination aus Opioid und alpha-adrenergem Agonisten in Schmerzmitteln
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
AU6836500A (en) 2001-03-19
JP2003513014A (ja) 2003-04-08
CZ2002516A3 (cs) 2002-05-15
CA2382648A1 (en) 2001-03-01
CN1368878A (zh) 2002-09-11
EP1210076A2 (de) 2002-06-05
SK2452002A3 (en) 2002-06-04
PL364871A1 (en) 2004-12-27
US20010053777A1 (en) 2001-12-20
DE19938823A1 (de) 2001-02-22
AR025329A1 (es) 2002-11-20
IL147643A0 (en) 2002-08-14
PE20010738A1 (es) 2001-07-16
CO5190708A1 (es) 2002-08-29
TR200200450T2 (tr) 2002-08-21
NO20020792D0 (no) 2002-02-18
UY26296A1 (es) 2001-04-30
MXPA02001295A (es) 2002-08-12
KR20020020273A (ko) 2002-03-14
NO20020792L (no) 2002-02-18
WO2001013903A3 (de) 2001-08-23
WO2001013903A2 (de) 2001-03-01

Similar Documents

Publication Publication Date Title
BR0013355A (pt) Tratamento com droga para a sìndrome da perna inquieta
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
BR0112962A (pt) Composições farmacêuticas para o tratamento de condições inflamatórias e ulcerativas dolorosas de maioria das superfìcies epiteliais tais como mucosite, estomatite e sìndrome de behcet
BR9807974A (pt) Composição farmacêutica para liberação prolongada de um derivado de eritromicina no ambiente gastrointestinal, e, processo para utilizar a mesma
BRPI0417072A (pt) agente preventivo para a vasculite
BR0317463A (pt) Métodos de triar para um composto que evita ou reduz a dissolução de um tetrâmero de transtiretina e de tratar uma doença amilóide transtiretina
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
BR0109779A (pt) Soluções moleculares hidrofìlicas dispersas de carvedilol
BR0115847A (pt) Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
BR9809951A (pt) Método para tratamento da obesidade
BR0013353A (pt) Combinação de substância ativa com clonidina
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
BRPI0406484A (pt) Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0309421A (pt) Composições de proteìna associada com corpo oleoso e métodos de uso destas para reduzir o risco de doença cardiovascular
BR9912223A (pt) Agente terapêutico para crise hipercalcêmica
BR0210744A (pt) Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes
BR0008302A (pt) Uso de um derivado de benzaldeìdo, derivado de benzaldeìdo, composição farmacêutica, e, processo para a fabricação da mesma
AR023699A1 (es) Una composicion farmaceutica que comprende un estabilizador de insulina y un procedimiento para preparar una composicion farmaceutica
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
ES2136581B1 (es) Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
BR0213696A (pt) Agonistas do receptor de acetilcolina nicotìnicos no tratamento da sìndrome de pernas inquietas
TR200103757T2 (tr) Apne, bulimi ve başka bozuklukların tedavi edilmesi için optik açıdan saf (-) norsisapridin kullanımı
IT1294931B1 (it) Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]